Biogen Idec (NQ:BIIB)
All News about Biogen Idec


This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
Via Benzinga







Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022
September 28, 2022
Via Benzinga



Via Benzinga

Via Benzinga
















Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.